Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in Europe:
UCB Sa
of BELGIUM
(2019
sales of 4.91 billion Euros [US$5.77 billion]
of which 35%
was Cimzia),
Protek PAO
of RUSSIAN FEDERATION
(265.65 billion Russian Rubles [US$3.63 billion]
of which 70%
was Distribution), and
Lonza Group AG
which is
based in SWITZERLAND
(5.92 billion Swiss Francs [US$6.46 billion]
of which 70%
was Pharma&Biotech).
Sales Analysis.
Grifols SA reported sales of 5.10 billion Euro (US$5.98 billion)
for the
year ending
December of 2019.
This
represents
an
increase of 13.6%
versus 2018, when the company's sales were 4.49 billion Euro.
Sales at Grifols SA have increased during each of the previous five years
(and since 2014, sales have increased a total of 52%).
Sales of Bio Supplies saw an increase
that was more than double the company's growth rate: sales were up
59.6% in 2019, from
167.00 million Euro to 266.54 million Euro.